What it sells
RNA intelligence for precision medicine
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical development / biomarker heads at pharma.
Trigger: what makes them buy now?
Costly trial failures from crude biomarkers; need patient selection and prognosis.
Workflow: what inputs become what output?
Train RNA foundation models on tumor bulk RNA-seq to produce disease-trajectory scores for covariate adjustment and responder selection.
Economics: what it saves and how it charges
Partnership/collaboration model with pharma; claims fewer patients needed for power; $7.2M seed (May 2026).
Distribution: how it reaches customers
Request early access; direct collaborations.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2025 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.